BofA raised the firm’s price target on AbbVie to $160 from $158 and keeps a Neutral rating on the shares. AbbVie reported a strong Q3 and raised 2024 floor EPS to $11.00, the firm highlights in a research note on Friday. Normally, this would have driven shares higher, but an update in the floor EPS guide was widely anticipated with further uncertainty from the Aesthetics business, BofA adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ABBV:
- Early notable gainers among liquid option names on October 30th
- Abbvie Reports Earnings: Did it Beat Estimate Forecasts?
- Piper buyers on AbbVie weakness, raises price target raised to $175
- AbbVie sees FY23 revenue about $54B, consensus $50.51B
- AbbVie sees Q4 adjusted EPS $2.87-$2.91, consensus $2.66